GT-389-255(GT-389-255) - 药物靶点：Lipase_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Lipase

作用机制

脂肪酶抑制剂

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

肥胖

原研机构

Genzyme Corp.

在研机构-

非在研机构

Genzyme Corp.

Peptimmune, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 GT-389-255 相关的临床结果

登录后查看更多信息

100 项与 GT-389-255 相关的转化医学

登录后查看更多信息

100 项与 GT-389-255 相关的专利（医药）

登录后查看更多信息

1

项与 GT-389-255 相关的文献（医药）

2006-04-01·Current opinion in investigational drugs (London, England : 2000)

Obesity drugs in clinical development.

Review

作者: Halford, Jason C G

A number of anti-obesity drugs are currently undergoing clinical development. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1 (exenatide, exenatide-LAR and liraglutide), peptide YY (intranasal PYY3-36 and AC-162325) and amylin (pramlintide); (iii) drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and (iv) a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown. Of these, only rimonabant has got as far as completing phase III clinical trials. This review will provide an overview of the most prominent drugs currently undergoing clinical development as potential anti-obesity therapies.

100 项与 GT-389-255 相关的药物交易

登录后查看更多信息